Event

2021 HPTN Annual Meeting

Virtual

The 2021 HPTN Annual Meeting took place virtually May 17, 19, and 21. The meeting featured a variety of HIV and COVID-19 prevention research presentations and discussions, as well as interactive Q&A sessions. 

View Recordings

Presentations

SURVIVING SARS-COV2: LESSONS FROM 40+ YEARS OF HIV RESEARCH – Dr. Myron S. Cohen

HPTN: SCIENTIFIC AIMS FOR 2021 AND BEYOND – Dr. Wafaa M. El-Sadr

MULTIPURPOSE PREVENTION TECHNOLOGIES FOR HIV PREVENTION: THE VISION, THE APPROACHES, AND THE CHALLENGES – Dr. Julie Pulerwitz and Dr. Lisa Haddad

CABOTEGRAVIR ROUNDTABLE DISCUSSION: PAST, PRESENT AND FUTURE 

HPTN 083: HIV VIROLOGY AND DRUG RESISTANCE  IN THE SETTING OF CAB LA PREP – Dr. Susan Eshleman

HIV PREVENTION AND THE VAGINAL MICROBIOME – Dr. Betsy Herold

SOURCE AND RECIPIENT CHARACTERISTICS OF HIV TRANSMISSION PAIRS IDENTIFIED IN THE HPTN 071 PHYLOGENETICS PROJECT – Dr. Matthew Hall

NIAID PRIORITIES IN HIV/AIDS RESEARCH – Dr. Anthony S. Fauci

PREP SCALE-UP, SUCCESS AND CHALLENGES – Dr. Rachel Baggaley

HPTN 094: A PERSON-CENTERED, PUBLIC HEALTH APPROACH TO ADDRESS HIV AND THE U.S. OPIOID CRISES – Dr. Steven Shoptaw

HPTN 096: INTEGRATING MULTI-LEVEL STRATEGIES TO REDUCE HIV TRANSMISSION AMONG BLACK MSM IN THE SOUTHERN U.S. – Dr. LaRon Nelson

CLASSES OF SEXUAL IDENTITY, HOMOPHOBIA, AND SEXUAL RISK AMONG BLACK SEXUAL MINORITIES IN HPTN 061 – Dr. Rodman Turpin

AN EXAMINATION OF PERCEIVED AUTONOMY SUPPORT, CARE COORDINATION QUALITY, AND PREP DISCONTINUATION AMONG BLACK MSM IN THREE U.S. CITIES: HPTN 073 – Dr. Raquel Ramos

HIGHER COLORECTAL TISSUE INFECTIVITY IN HIV SERONEGATIVE CISGENDER WOMEN COMPARED TO MSM BOTH WITH & WITHOUT ORAL ANTIRETROVIRAL (ARV) PREP REGIMENS IN HPTN 069 STUDY – Dr. Rogers Sekabira

FACTORS ASSOCIATED WITH DAILY AND NON-DAILY SEX-RELATED PREP ADHERENCE AMONG WOMEN IN CAPE TOWN IN THE HPTN 067/ADAPT STUDY – Elzette Rousseau

SEXUAL RISK PROFILES AMONG BLACK SEXUAL MINORITY MEN: IMPLICATIONS FOR TARGETED PREP MESSAGING: HPTN 073 – Dr. Derek Dangerfield II

IDENTIFYING PREDICTIVE FACTORS FOR CONDOM USE IN MSM AND TGW IN SUB-SAHARAN AFRICA: RESULTS FROM HPTN 075 – Dr. Anita Marais

HPTN 091: LESSONS LEARNED INCORPORATING LIVED EXPERIENCES TO STRENGTHEN RESEARCH DESIGN – Nora Howell

USING CROSS-SECTIONAL RECENCY ASSAYS TO ASSESS PREVENTION EFFICACY: FUTURE TRIAL DESIGN AND SAMPLE SIZE CONSIDERATIONS – Dr. Fei Gao

WHAT IS A WIN? DEFINING EFFICACY GOALS IN A TRIAL DESIGNED WITH A PLACEBO COUNTERFACTUAL – Dr. Jim Hughes

ESTIMATING THE EFFICACY OF LONG-ACTING PREP WITH A MODEL-BASED COUNTERFACTUAL PLACEBO – Dr. Mia Moore

ESTIMATING THE IMPACT OF PREP REGIMENS CONTAINING LONG-ACTING INJECTABLE CABOTEGRAVIR OR DAILY ORAL TDF/FTC AMONG MEN WHO HAVE SEX WITH MEN IN THE UNITED STATES: MATHEMATICAL MODELLING FOR HPTN 083 – Dr. Kate Mitchell

NETWORK AWARDS – Dr. Quarraisha Abdool Karim